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Human immunodeficiency virus type 1 (HIV-1) vaccine development requires selection of appropriate envelope (Env) immuno-
gens. Twenty HIV-1 Env glycoproteins were examined for their ability to bind human anti-HIV-1 monoclonal antibodies
(MAbs) and then used as immunogens in guinea pigs to identify promising immunogens. These included five Envs derived from
chronically infected individuals, each representing one of five common clades and eight consensus Envs based on these five
clades, as well as the consensus of the entire HIV-1 M group, and seven transmitted/founder (T/F) Envs from clades B and C.
Sera from immunized guinea pigs were tested for neutralizing activity using 36 HIV-1 Env-pseudotyped viruses. All Envs bound
to CD4 binding site, membrane-proximal, and V1/V2 MAbs with similar apparent affinities, although the T/F Envs bound with
higher affinity to the MAb 17b, a CCR5 coreceptor binding site antibody. However, the various Envs differed in their ability to
induce neutralizing antibodies. Consensus Envs elicited the most potent responses, but neutralized only a subset of viruses, in-
cluding mostly easy-to-neutralize tier 1 and some more-difficult-to-neutralize tier 2 viruses. T/F Envs elicited fewer potent neu-
tralizing antibodies but exhibited greater breadth than chronic or consensus Envs. Finally, chronic Envs elicited the lowest level
and most limited breadth of neutralizing antibodies overall. Thus, each group of Env immunogens elicited a different antibody
response profile. The complementary benefits of consensus and T/F Env immunogens raise the possibility that vaccines utilizing
a combination of consensus and T/F Envs may be able to induce neutralizing responses with greater breadth and potency than
single Env immunogens.
Amajor challenge for human immunodeficiency virus type 1(HIV-1) vaccine development is to design immunogens that
can overcome HIV-1 diversity and induce T and B cell responses
that cross-react with a majority of HIV-1 transmitted/founder
virus strains (1, 2). A number of strategies have aimed to induce
broad T cell responses, including mosaic (3), ancestral or consen-
sus (1), and conserved region (4, 5) immunogen designs. Both
consensus and mosaic immunogens have been shown to induce
superior T cell responses in nonhuman primates compared to
wild-type HIV-1 immunogens (6–8). Consensus sequences in-
duced T cell responses that had greater cross-reactivity in terms of
breadth and depth than wild-type strains (7, 9, 10), and polyvalent
mosaic vaccine designs were able improve the cross-reactive po-
tential even more (6, 8, 11), raising the possibility that global cov-
erage of the diverse forms of the HIV M group might be achievable
for a T cell vaccine.
In contrast, induction of broadly neutralizing antibodies
(bNAbs) to HIV-1 Env (Env) has been more problematic, with no
vaccine designs to date inducing high levels of bNAbs at mucosal
surfaces (12). The inability of HIV-1 Env constructs to induce
bNAbs is likely to be due to multiple factors acting in concert,
including occlusion of bNAbs epitopes in the native trimer (13–
15), strain-specific differences in epitopes, the inability to mimic
tertiary and quaternary epitopes with monomeric gp120 (16, 17),
and host immune controls that prevent bNAbs maturation and
expression (18, 19). Nonetheless, Env immunogens must be anti-
genic with expression of conserved neutralizing determinants to
have a chance for induction of neutralizing antibodies with any
degree of breadth, where breadth is the extent to which antibodies
can neutralize diverse natural HIV isolates.
While transmitted/founder (T/F) viruses have subtle traits that
distinguish them from chronic viruses (20, 21), the advantage of
the selection of T/F viruses for candidate Env immunogens re-
mains unclear (22, 23). T/F Envs tend to have shorter variable
loops and/or fewer N-linked glycosylation sites; this pattern is
clearly evident in clades A, C, and D (24–26) but marginal in clade
B (24, 27, 28). Protein sequence signatures have been identified
that are associated with T/F viruses (27); these signatures may be
associated with Env expression levels (29). A critical question for
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HIV-1 vaccine development is to determine whether T/F HIV-1
Envs differ from chronic and consensus Envs in their ability to
induce antibody responses.
To address the need for developing criteria for the choice of
candidate Env immunogens, we have compared the antigenicity
and immunogenicity of T/F, chronic and in silico-designed con-
sensus recombinant Env proteins. We have produced a panel of 7
T/F Envs from clades B and C; 5 chronic Envs from clades A, B, C,
AE_01, and G; and 8 consensus Envs selected from clades A, B, C,
AE_01, and G, as well as group M global consensus Envs (1). We
then compared Env antigenicity by enzyme-linked immunosor-
bent assay (ELISA) and surface plasmon resonance (SPR) and
determined Env immunogenicity in guinea pigs.
We found chronic Envs induced low or moderate levels of
primarily tier 1 neutralizing antibodies, and scattered low-level
tier 2 antibodies. Consensus Env immunogens induced higher
levels of tier 1 neutralizing antibodies (NAbs) than chronic Envs
and moderate levels of NAbs against subsets of tier 2 Envs. T/F
Envs immunogens induced low but measurable levels of broad
NAbs, neutralizing both tier 1 and most tier 2 HIV-1 strains. We
have identified a subset of T/F and consensus Env candidates that
may have promise as immunogens alone or that have complemen-
tary neutralization profiles that may be more immunogenic as
polyvalent mixtures.
MATERIALS AND METHODS
Recombinant HIV-1 Env proteins. Table S1 in the supplemental material
lists all of the recombinant Envs produced for the present study. HIV-1
Env consensus subtype sequences of clades A, B, C, G, and CRF01_AE
Envs were derived by aligning complete Env sequences, including one
randomly selected Env per sampled infected individual, of each HIV-1
subtype in the 2003 database as described at http://hiv-web.lanl.gov
/content/hiv-db/CONSENSUS/M_GROUP/Consensus.html (see Table
S1 in the supplemental material) (1, 30). CRF01 is a circulating recombi-
nant form (CRF) that is a common lineage in Asia (31, 32) and is predom-
inantly clade E in Env. Subtype G is not very common globally; however,
CRF02 is another major epidemic lineage in west Africa with a recombi-
nant founder, and CRF02 is subtype G in Env (33). (http://www.hiv.lanl
.gov/content/sequence/HIV/CRFs/CRFs.html). These clade consensus
sequences are relatively stable over time, although they can shift slightly
from year to year based on new sample acquisition at the database; obvi-
ously, the most variable positions are particularly subject to change, al-
though such shifts are minor relative to between-patient sequence differ-
ences. We included two consensus sequences from different years, B clade
and M group consensus sequences from 2001 and 2003, to see how clade
consensus sequences derived from two different years compared as im-
munogens. Group M is the “main” group of HIV-1 and refers to a set
including all circulating HIV-1 clades and recombinants. Group M con-
sensus Env sequences (CON-S and CON-T) were derived by aligning
consensus sequences from HIV-1 subtypes A (including A, A1, and A2), B,
C, D, F (including F1 and F2), and G from the 2001 (CON-S) and 2003
(CON-T) HIV-1 sequence database and forming a consensus of the sub-
type consensus sequences (see Table S1 in the supplemental material) (1,
30). The wild-type subtype A, B, C, and CRF01_AE gp160 Env sequences
from HIV-1 primary isolates from chronically infected subjects were se-
lected from HIV-1 sequence database to be representative of their clades;
specifically, they were not outliers within a given clade (http://hiv-web
.lanl.gov) (Table S1). Finally, seven T/F HIV-1 Env genes were chosen for
expression, including five subtype B Envs (B.040, B.65321, B.6240,
B.62357, and B.9021) and two subtype C Envs (C.1086 and C.089). T/F
Envs were obtained from acutely infected HIV-1 subjects by single ge-
nome amplification (22). In one previous study, we found no difference
between gp140 and gp120 for the induction of neutralizing antibodies in
guinea pigs (9); in contrast, in another study, we found minor augmenta-
tion of both binding and neutralizing antibody induction with immuni-
zation with gp140 relative to gp120 (34). Env gp140 as immunogens may
also have advantages in that they contain membrane-proximal external
region (MPER) neutralization epitopes (35) and have more relatively con-
served T cell epitopes (2) than do gp120 Envs. Thus, for these immuno-
genicity studies, we used gp140 oligomeric constructs.
All HIV-1 Env genes were codon optimized by converting amino acid
sequences to nucleotide sequences employing the codon usage of highly
expressed human housekeeping genes (36) and de novo-synthesized as
gp140 (see Table S1 in the supplemental material). HIV-1 gp140 Envs
with deletion of the cleavage (C) site and fusion (F) domain are termed
HIV-1. gp140CF; HIV-1 gp140 Envs with CF deletions and as well dele-
tions in the immunodominant (I) region in gp41 are termed gp140CFI
(9), and HIV-1 gp140 Envs with the deletion of only the cleavage (C) are
termed gp140C (Fig. 1A; see Table S1 in the supplemental material). All
group M and subtype A, B, C, G, and AE01 consensus and wild-type
HIV-1 gp140s were expressed as recombinant vaccinia viruses (rVVs) as
described previously (9). All T/F HIV-1 gp140C Env genes were cloned
into a mammalian expression plasmid pcDNA3.1/hygromycin (Invitro-
gen, Grand Island, NY). Recombinant Env glycoproteins were purified
using Galanthus nivalis lectin-agarose (Vector Laboratories, Burlingame,
CA) column chromatography from supernatants of 293T cell cultures
either infected with rVVs or transfected with the HIV-1 gp140C-express-
ing pcDNA3.1 plasmids and stored at 80°C until use.
The gel patterns of HIV-1 Envs proteins analyzed in blue native gels
are reproducible. For CON-S gp140, we have produced more than 50
individual batches of proteins, and CON-S gp140 has always had the same
gel pattern with predominant dimers and trimers, while clade C Envs,
such as 1086C, DU123, and C.con, from different batches consistently
migrate as trimers in blue native gels.
MAbs and soluble CD4. Monoclonal antibody (MAb) b12 was pro-
duced by Quality Biological, Inc. (Gaithersburg, MD). MAbs 2G12, 2F5,
and 4E10 were produced by Polymun Scientific (Vienna, Austria). MAbs
PG9 and PG16 were gifts from D. Burton (Scripps Research Institute, La
Jolla, CA); MAbs VRC01, VRC02, and VRC03 were gifts from J. Mascola
(National Institutes of Health [NIH], Vaccine Research Center, Bethesda,
MD); and MAbs to the C1 region of HIV-1 Env (A32) (37) and the CCR5
bs (17b) (38) were kindly provided by James Robinson (Tulane Medical
School, New Orleans, LA). MAbs to the V2 loop of HIV-1, 697D (39) and
2158, were kindly provided by Susan Zolla-Pazner. Soluble CD4 (sCD4)
was obtained from the NIH AIDS Research and Reference Reagent Pro-
gram (Bethesda, MD). T8 is a murine MAb that binds to the gp120 C1
region (a gift from P. Earl, NIH).
Blue native polyacrylamide gel electrophoresis (BN-PAGE) and
SDS-PAGE analysis of recombinant HIV-1 Envs. BN-PAGE analysis of
recombinant gp140 Env proteins was carried out as described previously
(9, 40–42). Briefly, purified HIV-1 Env glycoproteins were diluted in a
buffer containing 50 mM MOPS (morpholinepropanesulfonic acid), 50
mM Tris-HCl (pH 7.7), 20% glycerol, and 0.05% Coomassie blue. Protein
samples were loaded onto a 3 to 8% Tris-acetate NuPAGE gel (Invitrogen,
Carlsbad, CA), and electrophoresis was carried out for 1.5 h at 150 V with
50 mM MOPS–50 mM Tris-HCl (pH 7.7)– 0.03% Coomassie blue as the
cathode running buffer and 50 mM MOPS–50 mM Tris-HCl (pH 7.7) as
the anode buffer. To determine what forms of oligomers were recognized
by select HIV-1 MAbs, after BN-PAGE analysis and transfer onto nitro-
cellulose filters, HIV-1 gp140 proteins were probed with MAbs 2F5, PG9,
CH31, and 17B and detected by with goat anti-human whole IgG specific
(heavy- and light-chain)-AP (1:3,000 dilution) (Sigma, St. Louis, MO).
The immunoblots were developed with Western-blue substrate (Pro-
mega, Madison, WI). HIV-1 gp140 proteins were also analyzed in SDS-
PAGE under nonreducing and reducing conditions to ensure no major
degradations of the HIV-1 gp140 preparations used in the study.
ELISA. The reactivities of HIV-1 Envs with select HIV-1 MAbs and
serum antibodies of immunized guinea pigs with autologous HIV-1 Env
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and select HIV-1 V3 peptides were tested in ELISA as described previously
(43). To probe the antibody specificity induced by HIV-1 Env proteins,
sCD4 protein, MAbs 2F5, PG9, CH31, and 17B were biotinylated and used
as targets. Blocking the binding of biotinylated sCD4 protein and MAbs to
HIV-1 Envs by immunized guinea pigs serum antibodies was also deter-
mined by ELISA. Briefly, purified HIV-1 Env proteins (1 g/ml) in coat-
ing buffer (0.1 M NaHCO3 [pH 9.6]) were used to coat 384-well high
binding ELISA plates at 15 l/well at 4°C overnight. The plates were
washed with superwash (1% Tween 20, phosphate-buffered saline [PBS])
and blocked with 40 l of superblock (4% wheat protein, 1.5% goat se-
rum, 0.5% Tween 20, and 0.05% sodium azide in PBS)/well at room
temperature for 1 h. The blocked plates were washed with superwash and
then incubated with 10 l/well antibody in superblock at room tempera-
ture for 1.5 h. All MAbs were tested in serial dilution with a typical starting
concentration of 50 g/ml and no less than 20 g/ml. After incubation,
these plates were washed twice with PBS and then incubated with horse-
radish peroxidase (HRP)-conjugated goat anti-human IgG (1:5,000 dilu-
tion in 5% goat serum-PBS) at room temperature for 1 h. These plates
were then washed four times with PBS and developed with 30 l of TMB
substrate (SureBlue Reserve, Gaithersburg, MD)/well. The HRP reaction
was stopped with 30 l of 1 M HCl/well, and the well optical density was
determined at 450 nm. To determine antibody titers, pre- and postimmu-
nization serum samples of guinea pigs were tested in 3-fold serial dilutions
(from 1:30 to 1:5,314,410). Half-maximal effective concentrations (EC50)
of antibody binding titers were determined as described previously (43).
SPR. Surface plasmon resonance (SPR) assays were performed on a
BIAcore 3000 instrument and analyzed with BIAevaluation 3.0 software
(BIAcore, Inc., Uppsala, Sweden) as described previously (9, 44). Briefly,
anti-human IgG Fc antibody (Sigma Chemicals) was immobilized on a
CM5 sensor chip to about 12,000 to 14,000 response units (RU), and each
antibody was then captured to about 1,000 to 2,000 RU on individual flow
cells of the same sensor chip. Env proteins were injected in the solution
phase at 100 g/ml for 1 min over each of the flow cells. Nonspecific
binding of Env proteins to the captured control Synagis (anti-RSV) MAb
was subtracted from each binding curve (9, 44).
Animals and immunizations. Outbred guinea pigs were purchased
from Jackson Laboratory and housed in the vivarium at Duke University
Animal Research Facility. Animals were studied under a protocol ap-
proved by the Animal Use and Care Committee of Duke University.
Guinea pigs (four animals per immunogen group) were immunized in-
tramuscularly on day 0 and weeks 3, 6, 9, and 12 with 100 g/injection of
recombinant HIV-1 Env gp140 adjuvanted with type B oCpG in Emulsi-
gen (MVP Technologies, Omaha, NE). Serum samples were collected 10
days after each immunization and stored at 30°C until use.
Neutralization assays. Serum neutralizing antibody levels were mea-
sured against a panel of pseudotyped HIV-1 viruses containing Envs from
subtype B (B.QH0692, B.SF162, B.SS1196, B.BaL, B.BG1168, B.3988
B.WITO [from acute HIV-1 infection], and B.6101 [from acute HIV-1
infection]), subtype C (C.TV-1, C.DU123, C.DU172, C.92ZM233M,
C.92BR025, C.92ZM197M, C.96ZM651, C.DU151, C.97ZA012,
C.DU422, C.DU156, C.02ZM233M, and C.02ZM197M), subtype A
(A.92RW010, A.92UG37, A.93TH976.01, A.Q23, A.Q168, A.Q259,
A.Q461, A.Q769, and A.Q842), and a single circulating recombinant form
CRF01_AE Env, AE_93TH976 (45). Neutralization assays were based on
reductions in luciferase (Luc) reporter gene expression after a single
round of virus infection with pseudotyped HIV-1 viruses in TZM-bl cells
(25, 46–48). For each assay, serum samples were collected prior to vacci-
nation (prebleed) and postvaccination (postbleed) from guinea pigs and
FIG 1 HIV-1 Env designs used in the study. (A) Schematic representation of HIV-1 gp160, as well as recombinant HIV-1 gp140C with a deletion of the cleavage
site (C) in the junction of gp120 and gp41 by the mutation of two Arg residues to Glu residues as indicated; gp140CF with deletion of the cleavage site and the
fusion domain (CF); and gp140 CFI with deletions of the cleavage site, fusion domain, and immunodominant domain (CFI). (B) Blue native PAGE analysis of
HIV-1 gp140 Envs. Names of individual Env proteins are shown on the top of the lane. Arrowheads indicate the monomeric, dimeric, trimeric, and tetrameric
forms of gp140.
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assayed against individual pseudotyped HIV-1 viruses and also tested
against murine leukemia virus (MuLV) as a negative control.
We performed parallel analyses of neutralization data using two cate-
gorizations of neutralization data. The first was a traditional strategy,
typical of what we and others have used in the past. Here, we considered a
neutralization value positive only if the neutralization titer was 3-fold over
both the prebleed level and the level seen with the MuLV control, and the
value of the experimental neutralization titer was 30. Samples that did
not meet these criteria were considered equivalent to below the threshold
of detection (20). We refer to this as the “traditional approach.” When
applying this method, we noted that we were frequently disregarding low
levels of postbleed activity that were reproducibly above background in all
four animals in a group, but not 3-fold above background, and it is not
known whether such low-level responses may be useful in a vaccine con-
text. To have greater confidence in measures of low-level activity, for every
guinea pig that had a higher than background prevaccination spurious
NAb activity in its sera, IgG was purified from both pre- and postbleed,
and purified IgG was used instead of sera from those animals to test the
NAb response to the immunogen. The IgG levels were brought to a con-
centration equivalent to the IgG level in serum, so the titers were equiva-
lent. A high prebleed background was essentially removed by this step.
Thus, we also analyzed the data considering all 50% infective doses (ID50)
and values above the background, including the IgG purification step for
all animals with high prebleed values. We refer to this as the “inclusive
approach.” Using this approach, low-level responses against the panel of
Envs were more reproducible within a group of animals that received the
same immunogen than when using the traditional approach (see Results).
We included both the traditional approach, because it is the way such data
have been analyzed in the past, and the inclusive approach, because the
results were more consistent between animals and the increased sensitiv-
ity might be relevant to human studies, in parallel analyses presented
throughout the present study. In our inclusive analysis, values that were
recorded as “20” and so were below the threshold of detection were re-
placed with “10,” as were any values less than the controls. Left censored
data points were replaced with their lower limits (i.e., 540 and 43,740,
respectively). Our “traditional analysis” was similar except that any
postimmunization data point that was 3 times the preimmunization
bleed was also replaced with a 10.
Analysis and statistical methods. (i) Hierarchical clustering. Neu-
tralization data were organized by hierarchical clustering so that sim-
ilar patterns of NAb susceptibility among pseudovirions and similar
patterns of NAb response among immunogens could be grouped and
displayed using a heat map and dendrogram clustered according to
distances between vectors of log ID50 NAb scores using the Los Alamos
HIV database tool heat map (http://www.hiv.lanl.gov/content
/sequence/HEATMAP/heatmap.html). Euclidean distances and the
average clustering method were used to create the dendrograms. This
tool uses the statistical package R (49).
(ii) Nonparametric statistics used to compare distributions of val-
ues among consensus, T/F, and chronic immunogen sets. The analysis
was conducted using a Kruskal-Wallis test for omnibus effects and Wil-
coxon tests for pairwise effects. We used these nonparametric methods to
obviate any potential violations of normality assumptions. The z approx-
imation was used to determine significance when there were ties in the
data. These standard tests were performed using either the R package (49)
or SAS v9.2. Benjamini-Hochberg (50) false discovery rates (FDR) to ad-
just for multiple tests were computed using PROC MULTTEST in SAS
v9.2.
(iii) GLM analysis. Because the data were heavily censored, they did
not have a log-normal distribution but were markedly skewed with a bolus
of points recorded as 20 or below the threshold of detection. (There
were 3,015 tests performed, and 1,209 of 3,015 (40%) were recorded as
20; a few other measurements lay above the threshold of the assay, with
36 of 3,015 recorded as 540 [1.2%] and 5 of 3,015 recorded as 43,740
[0.17%]). We compared a Gaussian model, an inverse Gaussian model,
and several models designed to address censored data that are discussed
below. All modeling and model comparisons were done using the R pack-
age (49). For these data, using both the conserved and inclusive cutoffs,
the inverse Gaussian model was significantly better by Akaike’s informa-
tion criterion; thus, it was used for the generalized linear model (GLM)
comparison. The two approaches we tested designed to handle censoring
were the “lmec” (linear-mixed-effects model for left censored data imple-
mented in the R lmec package) and the MCMCglmm algorithm (for
fitting generalized linear mixed effects models for left, right, or interval
censored data in the R MCMCglmm package). The results obtained in
each censored data model were consistent with those obtained in the
normal fit and the inverse Gaussian mode, but the latter provided a
better fit.
For the model, let yi be the log10 titer observed for guinea pig i. Also, let
the regression coefficient k,0 represent the effect of the k
th immunogen
relative to a specified reference immunogen, where k,0  0 represents no
difference between the kth immunogen and the reference immunogen,
k,0  0 indicates that a stronger immune response was elicited by the k
th
immunogen relative to the reference, and k,0  0 indicates a weaker elicited
response. Finally, let Gi be an intercept, which augments the immunogen
effect for a particular guinea pig. The model of the mean log10 titer response is:
E[yi]  0  1,0 Immunogen1 [r] 2,0 Immunogen2  . . . [r] 19,0 Im-
munogen19  Gi, where Immunogenk is an indicator variable, so that Immu-
nogenk  1 if guinea pig i received the reference immunogen and is zero
otherwise. Further, Immunogenk  0 for all k if guinea pig i received the
reference immunogen. In the following development, we consider models
whose reference immunogens were those that produced the strongest re-
sponses. CON-S gave the highest overall levels of response, so all other vac-
cines are measured relative to CON-S.
(iv) Model-fitting using the censored data strategy that estimated
the probability of a response. Model fitting and figure preparation used
(i) the statistics package R (49), supplemented with the packages GAMLSS
(51), used to fit Gaussian models to the censored titer data, (ii) multcomp
(52), used to make multiple comparisons, and (iii) the suite of utilities
called BSagri (53).
RESULTS
Production of HIV-1 Env gp140 oligomers. To examine and
compare the antigenicity of consensus, chronic, and T/F HIV-1
gp140 Envs, the HIV-1 gp140s in Table S1 in the supplemental
material were expressed and purified. Purified HIV-1 Env gp140C
oligomeric proteins migrated in blue native gels as dimers, trim-
ers, and tetramers (Fig. 1B) with no major degradation in SDS-
PAGE under reducing and nonreducing conditions (see Fig. S1 in
the supplemental material). In contrast, subtype C HIV-1 gp140
Envs of consensus, chronic, and T/F Envs migrated predomi-
nantly as trimers (Fig. 1B). The glycosylation status of several
HIV-1 Env proteins included here has been studied in detailed by
mass spectrometry (40, 54–56). The carbohydrate composition of
the same HIV-1 gp140 construct produced in 293T cells by either
recombinant vaccinia virus or by transfection was analyzed, and
we found essentially no change in the glycosylation between the
two samples (E. Go, H.-X. Liao, B. Haynes, and H. Desaire, un-
published data).
Binding reactivity of HIV-1 MAbs to Env gp140 proteins. The
antigenicity of the three groups of HIV-1 gp140 Envs were tested
and compared using ELISA (Table 1) and SPR (Table 2) for their
ability to bind a panel of HIV-1 Env antibodies including CD4
binding site antibodies, b12, and VRC01, VRC02, and VRC03
from a related lineage; CCR5 coreceptor binding site (CCR5 bs)
MAb 17b; glycan antibody 2G12; quaternary antibodies PG9 and
PG16, a pair from a related lineage; and MPER MAbs 2F5 and
4E10. The relative binding affinity of each of the individual HIV-1
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Envs to specific antibodies measured by ELISA (EC50, nM) and
SPR (response unit) are summarized in Tables 1 and 2. Of note,
consensus proteins are artificial constructs, a concatenation of the
most common form of each amino acid in each position in an
alignment. Thus, HIV-1 population consensus sequences con-
tained combinations of amino acids that are not found in nature,
and there is always a concern that they may not fold appropriately.
Therefore, the consistency of binding of antibodies with discon-
tinuous epitopes to the consensus sequences was reassuring.
CON-S gp140 Env bound with the highest affinity among the
consensus sequences, and the only MAb tested that did not bind to
CON-S was VRC03 (Tables 1 and 2). VRC01 and VRC02 are de-
rived from the same clonal lineage as VRC03 (57), and these two
MAbs did bind to CON-S with high affinity. The only consensus
Env that did not bind to most MAbs tested was A1.con.
We next compared the overall binding scores of the consensus,
chronic, and T/F Envs to the panel of MAbs in shown in Tables
and 1 and 2. We first used the nonparametric Kruskal-Wallis om-
nibus test to determine whether, for a given antibody, one of the
three groups was distinct from the others, followed by Wilcoxon
pairwise comparisons. VRC01, VRC02, and VRC03 were all de-
rived from the same clonal lineage, with VRC01 being most potent
neutralizing MAb among them (57). PG9 and PG16 are similarly
clonally related, with PG9 being the most potent (17). Thus, only
VRC01 and PG9 were used in the statistical comparisons, to rep-
resent the two lineages and minimize the number of tests. Because
multiple tests were performed, we performed an FDR compari-
son. The T/F binding tended to be higher in number of epitopes
expressed, and the binding of MAb 17b was significantly different
between the three groups; 17b had significantly higher binding
affinity for T/F viruses (Tables 1 and 2 and see Table S2 in the
supplemental material, false discovery adjusted P value  0.02 for
ELISA, 0.03 for SPR). 17b is a CD4-inducible antibody that binds
near the CCR5-coreceptor binding site (38) and, interestingly,
increased T/F binding affinity was observed even though sCD4
was not present in the binding assay. Similar reactivity patterns of
MAbs 2F5, PG9, CH31, and 17b with HIV-1 Envs detected by
ELISA and by SPR were also observed in BN-PAGE Western
blot analysis. When these MAbs did bind to HIV-1 Envs, MAb
2F5 had the strongest reactivity and recognized all forms of
gp140 oligomers, whereas the PG9, CH31, and 17B primarily
recognized dimers, trimers, and oligomers but also recognized
the gp140 monomer weakly or not at all (see Fig. S2 in the
supplemental material).
Immunogenicity of T/F, chronic, and consensus Envs. Next,
the 20 gp140 Envs in Table S1 in the supplemental material were
used to immunize guinea pigs. Most consensus gp140 sequences
were based on the database from 2003; two B clade consensus Envs
(B.con_01 from 2001 and B.con_03 from 2003) and two group M
consensus Envs (CON-S from 2001 and CON-T from 2003) were
included in the immunogenicity studies to ensure that we were
not missing minor Env changes that might lead to induction of the
breadth of responses. The immune responses elicited were indeed
somewhat different when using immunogens from different years
TABLE 1 Binding reactivity of HIV-1 Envs to HIV-1-specific MAbs in ELISAa
a *, No binding detected at 20 mg/ml.
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(Fig. 2). The T/F Envs were from 2005 to 2007 isolates (22). NAb
responses to these HIV-1 Envs were evaluated using a panel of 36
Env-pseudotyped viruses from clades A, B, C, and CRF01_AE (see
Table S3 in the supplemental material).
Bar plots illustrating the relative potency of ID50 NAb re-
sponses elicited by each immunogen against each of the pseudo-
virus Envs are shown in Fig. 2 and Fig. S1 in the supplemental
material (Fig. 2 shows the geometric mean response for each im-
munized group of four animals to each Env; Fig. S3 in the supple-
mental material illustrates the same data, but the results for each
animal are shown individually). As described in Materials and
Methods, we analyzed the data using two strategies: a traditional
approach (Fig. 2A), in which a positive neutralization value of
immune guinea pig serum had to be at least three times higher
than both the prebleed serum and the negative control virus
MuLV-SVA to be considered positive, and an inclusive approach
where IgG was purified to minimize background, and then any
responses that were above both negative controls were considered
positive (Fig. 2B). By definition, more reactions were deemed pos-
itive when using the inclusive method (Fig. 2A compared to
Fig. 2B). Using both data interpretation strategies, a pattern is
evident that is associated with each of the classes of immunogens.
Consensus sequence immunogens tended to have the greatest re-
sponses to tier 1 Envs (45) and elicited a moderately high level of
response to a subset tier 2 Envs. T/F immunogens gave low levels
of response across most Envs tested, but with greater breadth than
consensus immunogens. Chronic Env immunogens showed
moderate to low-level responses to some tier 1 Envs and sporadic
low responses to tier 2 Envs (45). Within-clade matched responses
are indicated by the colors in Fig. 2. Little clade specificity was
manifested in these data, although occasionally it is evident. For
example, the B.con.03 responses favored B clade pseudoviruses.
Of note, the B and C clade T/F viruses did not elicit markedly
stronger responses within clades than between clades (Fig. 2).
Heat maps, organized by two-dimensional hierarchical clus-
tering, further illustrate the over distinctive patterns between con-
sensus T/F and chronic immunogens. The traditional threshold
data heat map is shown in Fig. 3A, with the inclusive method of
analysis in Fig. 3B. In these heat maps, pseudotyped Envs with
similar susceptibility patterns are clustered together and, likewise,
immunogens that elicited antibodies that had similar neutralizing
susceptibility are clustered together, regardless of their classifica-
tion as T/F, consensus, or chronic. Between three and seven ani-
mals per immunogen group were tested. The three patterns asso-
ciated with chronic, T/F, and consensus immunogens are clearly
discernible (Fig. 3). The chance that the animals who received the
same type of immunogen would cluster according to reactivity
pattern to the extent observed in the heat maps is very small if you
consider each animal separately (P  2  1016, the Fisher exact
test for a 33 table for the traditional method, and P  0.0000002
for the inclusive method), and still low when animals given the
same immunogen are considered as a group rather than single
TABLE 2 Binding reactivity of HIV-1 Envs to neutralizing MAbs in SPR analysisa
a *, Below the threshold of detection using SPR.
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animals, and the group is assigned to the cluster that most of the
animals in the group fall into (P  0.003 for the conserved ap-
proach, P  0.01 for the inclusive). Although the distinct patterns
were statistically significant, there were a few exceptions to this
overall pattern. The T/F founder virus, C.1086, behaved more like
a consensus immunogen than the other T/F strains, in that C.1086
did not have great breadth, and it generates more intense tier 1
than tier 2 responses (for example, the C.1086-vaccinated animals
have a NAb profile very similar to that of the G consensus-vacci-
nated animals). Also, the two subtype B consensus sequences from
different years were subtype specific and elicited responses similar
to the chronic B clade isolate B.JRFL.
Hierarchical clustering strategy used to create the heat map
brought the replicate animals in 12 of the 20 immunogen groups
that received the same immunogen most closely together, when
the inclusive strategy was used (see brackets in Fig. 3B). This com-
pares with only 2 of 20 immunogen group clusters using the tra-
ditional method (see brackets in Fig. 3A) (P  0.002, calculated
using a Fisher exact test comparing inclusive versus traditional
strategies). This reflects the greater consistency of the response
data between animals that received the same immunogen when
the inclusive cutoff was used and is an indication that the inclusion
of low-level responses does not just add noise but rather captures
consistent reproducible patterns in the Env immunogen-induced
neutralizing responses.
Comparison of neutralizing breadth induced by T/F,
chronic, and consensus Env immunogens. For an initial compar-
ison of neutralizing breadth responses induced by the three classes
of Env immunogens, we counted the number of times an im-
munogen group of animals had at least two responding animals
that had detectable neutralizing titer for each of the 36 Envs and
compared the distribution of counts for groups of T/F, consensus,
and chronic immunogens (Fig. 4A and B illustrate the breadth of
Env responses among the 36 Env pseudovirions for each immuno-
gen using the traditional and inclusive strategies, respectively).
The omnibus Kruskal-Wallis test indicated that there was a signif-
icant difference among the distributions using the traditional ap-
proach (P  0.0027), and T/F Envs ranked significantly higher
than consensus Envs, which in turn were significantly higher than
chronic Envs (all P values of each pairwise comparison are pro-
vided in Fig. 4). Using the less stringent inclusive strategy (Fig.
4B), many more low responses against a spectrum of Envs were
FIG 2 Neutralization activity of guinea pig groups immunized with HIV-1 Envs. Geometric means of IC50 neutralization titers (y axis) for groups of guinea pig
that received the indicated HIV-1 Envs (grouped into consensus, T/F, and chronic families) were determined against a panel of subtype A, B, C, and E
pseudoviruses using the traditional approach (A) or the inclusive approach (B). The same color codes were used for each subtype for both Env immunogens, as
shown in the lower right portions of panels A and B. Pseudoviruses are ordered the same way in each panel, according to the key at the bottom, to facilitate
comparisons between vaccine responses.
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observed within all groups, and so the groups were not statistically
distinguishable, although there was a trend again suggesting that
T/F Envs induced a greater breadth of response than did chronic
Envs (P  0.061).
Comparison of the magnitude of responses to single im-
munogens. We initially used a generalized linear model to com-
pare the potency of the neutralizing antibody responses using the
different immunogens. The model selection is described in Mate-
rials and Methods; the model which fit the data the best was an
inverse Gaussian model, and animal-to-animal immune system
differences were accounted for by treating the interanimal varia-
tion as a random effect. The analysis requires as input both the
FIG 3 Heat maps reflecting HIV-1 neutralization activity of each individual guinea pigs immunized with HIV-1 gp140 Envs. The neutralizing activity of
individual guinea pigs immunized with a particular HIV-1 Env is presented as a heat map, with stronger neutralizing activity indicated by color, as shown in the
key at the upper left. Serum samples from individual guinea pigs are identified by a string beginning with the name of the HIV-1 Env used to immunize the animal,
followed by a unique guinea pig ID number. The panel of 36 HIV-1 pseudoviruses is listed at the bottom of the heat map, arranged in order of decreasing
susceptibility to neutralization. The neutralizing activity of individual guinea pig sera was analyzed using both the traditional approach (A) and the inclusive
approach (B).
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neutralization titers (one for each measured combination of ani-
mal and isolate) and a separate list of responses that should be
regarded as definitely positive, based on whether the traditional or
the inclusive approach described above is used. The CON-S im-
munogen showed the highest overall levels of response using both
traditional (Table 3) and inclusive (Table 4) threshold approaches
and so was used as the reference strain, and all other immunogens
were measured relative to CON-S. Using the traditional approach,
CON-S Env induced significantly greater antibody responses than
all other HIV-1 Env immunogens, and chronic responses, along
with T/F B.9201, ranked the lowest (Table 3). Using the inclusive
approach, CON-S again ranked the highest but was not statisti-
cally distinguishable from other consensus immunogens, includ-
ing CON-T, A1-con, C-con, and B-con_01; the CON-S response
was significantly higher than all T/F and chronic Env immuno-
gens.
Evaluation of neutralizing breadth versus strength of re-
sponses induced by consensus, T/F, and chronic Env immuno-
gens. To reexamine the question of breadth and depth in a prob-
abilistic framework, given our uncertainty about near-threshold
FIG 3 continued
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responses, we developed a new class of models designed to sepa-
rate the breadth of the NAb response—i.e., the number and vari-
ety of strains to which an immunogen induces a response—from
the strength of that response—i.e., the raw neutralizing power of
the sera from those animals in which the immunogen induces a
positive response. This model also incorporated a self-consistent
estimation process for the censored data. The resulting model has
two aspects: a binomial regression that produces a probability of
positive response for each combination of immunogen and isolate
and then, again for each immunogen-isolate combination, a pair
of linear regression models— one for the positive responses and
another for the negative ones—that predict the logs of the neu-
tralization titer.
The novelty of the approach is that we require internal consis-
tency between the two aspects of the model: if some immunogen-
isolate combinations produce only modestly strong positive re-
sponses, then it is possible that some near-threshold responses,
initially classified as negative, may contribute to a better-fitting
model if they are reclassified as weak, but positive responses. After
an initial round of parameter estimation, we assign a suitable pos-
itive weight to such near-threshold responses and fold them back
FIG 4 Comparison of breadth of antibody responses induced by HIV-1 T/F, consensus, and chronic Env immunogens. The breadth (the vertical axis shows the
percentage of the panel of 36 pseudoviruses neutralized, averaged across all immunized animals) for each of the individual HIV-1 Env immunogens (x axis) using
the inclusive approach (A) and the traditional approach (B). The immunogens were classed as T/F, consensus, or chronic Envs, and the P values are for
comparisons between these classes.
TABLE 3 Results of a model fit to the data with log10 neutralization
titers using traditional strategya
Vaccine Estimate SE t P
(Intercept)- CON-S 1.5 0.082 19 9.5  1075
C.con –0.21 0.11 –2 0.047
B.0040 –0.23 0.11 –2.1 0.034
C.089 –0.22 0.1 –2.1 0.033
C.1086 –0.25 0.1 –2.4 0.016
CON-T –0.27 0.1 –2.6 0.0084
B.63521 –0.28 0.1 –2.8 0.0058
B.62357 –0.29 0.1 –2.8 0.0044
B.con_01 –0.3 0.1 –2.9 0.0032
A1.con –0.3 0.1 –3 0.0029
AE.con –0.3 0.1 –3 0.0028
G.con –0.3 0.1 –3 0.0027
B.6240 –0.35 0.099 –3.6 0.00038
B.con_03 –0.37 0.099 –3.7 0.00002
G.DRCBL –0.38 0.098 –3.8 0.00014
B.JRFL –0.35 0.092 –3.8 0.00013
B.9021 –0.43 0.096 –4.5 0.0000062
A.00MSA –0.44 0.096 –4.6 0.0000040
AE.97CNGX2F –0.48 0.098 –4.8 0.0000014
C.DU123 –0.5 0.094 –5.3 0.00000012
a The results of a model fit to the data with the log10 titer. Con-S gave the highest
response in terms of the overall magnitude response and so was used as the reference
strain; the very low value P value associated with Con-S reflects that the Con-S vaccine
effect is not zero. The other vaccine estimates are negative values since they reflect the
overall potency of the response relative to Con-S, and the P value indicates whether this
difference is statistically significant. Vaccines are ordered according to their overall
magnitude.
TABLE 4 Results of a model fit to the data with log10 neutralization
titers using inclusive strategya
Vaccine Estimate SE t P
(Intercept)- CON-S 1.8 0.11 17 1.2  1061
CON-T –0.13 0.14 –0.92 0.36
A1.con –0.17 0.14 –1.2 0.24
C.con –0.21 0.14 –1.5 0.13
B.con_01 –0.22 0.14 –1.6 0.12
B.0040 –0.3 0.14 –2.2 0.031
C.1086 –0.29 0.13 –2.2 0.029
B.63521 –0.33 0.13 –2.5 0.012
C.089 –0.34 0.13 –2.6 0.009
AE.con –0.35 0.13 –2.7 0.0073
B.62357 –0.36 0.13 –2.8 0.0051
G.DRCBL –0.39 0.13 –3 0.0024
B.con_03 –0.4 0.13 –3.1 0.0018
G.con –0.4 0.13 –3.1 0.0017
B.JRFL –0.41 0.12 –3.4 0.00063
B.6240 –0.44 0.13 –3.5 0.00052
C.DU123 –0.44 0.13 –3.5 0.00045
A.00MSA –0.52 0.12 –4.3 0.000022
AE.97CNGX2F –0.55 0.13 –4.3 0.000017
B.9021 –0.55 0.12 –4.5 0.0000081
a See the footnote for Table 3.
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into the analysis, using the EM-algorithm (58) to repeatedly fit
parameters and reweight the data until we obtain a self-consistent
model.
As before, we fit models based on the two different positivity
criteria, the conserved and inclusive strategies. Using this model,
the conserved data fit better (in the sense of having the higher
log-likelihood), and so the parameters of conserved model are
illustrated in Fig. 5 and 6. Figure 5 shows the fitted probability of a
positive response as a function of immunogen-isolate combina-
tion. Using this measure and modeling the probability of a re-
sponse being positive (in contrast to our previous measure of
breadth in Fig. 4), the broadest neutralizing responses were in-
duced by the consensus Env AE.con, followed closely by the im-
munogens derived from the T/F strains B.63521, B.0040, and
C.089. The reason underlying this reordering compared to Fig. 4
can be understood by looking closely at the data in Fig. S3 in the
supplemental material; while AE.con has fewer detected re-
sponses, many of the responses to the T/F immunogens are bor-
derline, and when AE.con does have a response, it tends to be a
higher value and so is more likely to be rescored as positive in this
probabilistic model. Three of the four immunogens with the high-
est probability of response to the most Envs are T/F viruses, and
these three consistently yield great breadth by both measures
(Fig. 4 and 5).
The strengths of positive responses induced by different Envs
were also compared using this model and were consistent with the
findings reported above based on an inverse Gaussian GLM. The
consensus Envs as a class were by far the most effective at eliciting
potent responses (Fig. 6). If we again make suitably adjusted mul-
tiple comparisons between the two best immunogens from each
category, the best consensus Env, CON.S, produced significantly
stronger responses than any of the others (P  0.0233 for C.con,
the second best consensus, while P  0.001 for all T/F and chronic
Envs).
Serological analysis of serum antibodies induced by HIV-1
Envs. To determine whether differences in serum binding anti-
bodies induced by individual HIV-1 Env immunogens could con-
tribute to differences observed in neutralizing antibody responses,
we evaluated pre- and postimmunization sera in multiple epitope-
binding ELISAs. We found chronic and consensus Envs induced
comparable binding antibody responses to autologous Envs
(Fig. 7A), while significantly lower binding antibody titers were
induced by T/F Envs (P  0.005 compared to chronic Envs and
P  0.001 compared to consensus Envs [two-sided Wilcoxon rank
sum test]). Next, we probed the serum antibody specificities by
serum inhibition assays of biotinylated MAbs or sCD4 using the
MAbs 1b12, PG9, and 2G12. Serum antibodies blocked sCD4 and
MAb 1b12 binding to HIV-1 subtype B.JRFL gp140 and MAb PG9
binding to AE.A244 gp120 (Fig. 7B to D), while no induced 2G12
serum blocking antibodies were detected (Fig. 7E). Thus, CD4bs
and V2 region antibodies contribute to the immune responses in
consensus, chronic, and T/F immunizations. Serum antibodies
from animals immunized with T/F Envs tended to have the high-
est inhibition of sCD4 and 1b12 binding to JRFL gp140, followed
by consensus Envs and then chronic Envs (Fig. 7B and C), but the
distinction between classes of immunogen was not significant. In
contrast, chronic and consensus Envs induced antibodies that had
significantly higher inhibition of MAb PG9 binding to AE.A244
FIG 5 Heat map reflecting breadth of antibody responses induced by HIV-1 consensus, chronic, and T/F Env immunogens. Heat map showing the fitted
probability that a guinea pig in each of the individual immunization groups (rows) would have shown neutralizing activity against the panel of 36 HIV-1
pseudoviruses (columns). A higher probability of a positive response (traditional criterion) is indicated by a darker color, as detailed in the key at the upper left.
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gp120 than antibodies induced by T/F Envs (P  0.03 and P 
0.017, respectively) (Fig. 7D).
We detected V3 peptide binding antibodies in all immunized
guinea pig groups with robust reactivity to consensus subtypes B
and C and group M CON-S V3 peptides (see Fig. S4 and S5 in the
supplemental material). There was a within-clade preference in
the V3 responses, such that vaccines using an Env of a particular
clade tended to react most intensely with the consensus peptide of
that same clade, most likely due to higher degrees of sequence
similarity (see Fig. S4 and S5A to C in the supplemental material).
Consensus Envs induced the highest measured levels of V3 anti-
bodies relative to chronic or T/F Envs (Wilcoxon P  0.048 and
P  0.037, respectively) (see Fig. S5D in the supplemental mate-
rial), but consensus peptides were used to assess V3 reactivity, so
the consensus immunogens were either a perfect match or a closer
match to the test peptides than were natural strain immunogens,
which each had strain-specific differences in V3 (see Fig. S4 in the
supplemental material). The V3 regions were quite diverse among
the T/F and chronic immunogen sequences (see Fig. S4 in the
supplemental material). Thus, we could not resolve whether the
higher V3 peptide antibody responses observed among the con-
sensus immunized animals were due to a more intense V3 anti-
body response or simply the result of greater similarity with the V3
peptides used for testing. We had previously observed that the
CON-S neutralization of tier 1 Envs could be blocked by CON-S
V3 peptides (9). Consistent with this, the tier 1 neutralization
potency of consensus immunogens was highly correlated within-
clade V3 peptide binding (see Fig. S5E and F); i.e., the responses to
the V3 peptide based on the B.con sequence were highly correlated
with neutralization of the tier 1 virus SF162 (P  0.008), and the
responses to the V3 peptide based on the C.con sequence were
highly correlated with neutralization of the tier 1 virus C.BR025
(P  0.008) (see Fig. S5D and E in the supplemental material).
Neutralization of tier 2 viruses was not correlated V3 peptide re-
activity.
DISCUSSION
In this study, we produced a panel of 20 recombinant T/F,
chronic, and consensus gp140 Envs derived from 293T cells either
by transfection or recombinant vaccinia virus and then compared
them as Env immunogen candidates by antigenicity and immu-
nogenicity studies. First, we found that T/F, chronic, and consen-
sus Envs bound comparably to a panel of Env antibodies, with the
exception of increased CCR5 binding site antibody 17b to T/F
viruses. The CCR5 binding site region has been identified as a
focus of Env signature mutations associated with developing
bNAbs during chronic infection (59), and CD4-independent ex-
posure of this region is related to the intrinsic reactivity of an Env
protein (60), suggesting that epitope exposure of this region may
be an important aspect of the bNAb potential of an immunogen.
Second, we found that of the Envs, the best inducer of potency of
the NAb responses was the group M consensus Env, CON-S,
which had the highest magnitude of response to tier 1 and a subset
of tier 2 pseudotyped virions (45). In contrast, the T/F recombi-
nant Envs consistently outperformed both chronic and consensus
Envs in terms of the induction of antibodies with neutralization
breadth across all Envs tested, although these tended to be low
level, even against tier 1 viruses. One might expect the results with
FIG 6 Heat map showing the fitted strength (predicted log10 titer) of positive responses induced by HIV-1 immunogens. As in Fig. 5, rows correspond to
immunogens, whereas columns are labeled by the pseudovirus strain. The key at the upper left shows both the color scale (with the strongest predicted responses
corresponding to titers of 10,000, as seen for some tier 1 Envs) and the distribution of fitted values: many lie near log10(20) 	 1.3, indicating that some responses
near the threshold of the assay may be weak but positive.
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chronic and consensus Envs to be the same since the consensus
Env sequences are primarily derived from chronic-Env sequences.
However, because the consensus sequences are central, they are
likely to capture common recurring aspects of the virus. Thus,
while chronic infections after exposure to autologous NAbs may
regularly accrue characteristics that tend to make them more re-
sistant, such changes may also have fitness costs that are selected
against at transmission. Particularly if there are multiple pathways
to such chronic escape phenotypes, a population consensus would
not necessarily reflect them. Thus far, we have only tested five B
and two C clade T/F immunogens, and whether the observed pat-
terns will hold for T/F viruses of other clades remains to be deter-
mined. An alternative to T/F Envs being more broadly immuno-
genic than chronic Envs is that there may be clade-specific effects,
and the single B Env in the chronic HIV-1 group may not have
been comparable to the majority of clade B Envs in the T/F group.
The recombinant HIV-1 Envs in the present study all induced
antibodies that had high binding antibody titers to the autologous
Env and to V3 peptides and were capable of blocking the binding
of sCD4 and MAbs 1b12 and PG9 to HIV-1 Env proteins but were
not able to block MAb 2G12 binding to JRFL gp140. Despite the
complexity of the polyclonal immune responses, anti-V3 peptide
responses correlate strongly with potent tier 1 neutralization.
We recently demonstrated that the Thai RV144 HIV-1 vaccine
that resulted in an estimated vaccine efficacy of 31% in a phase III
trial correlated directly with antibodies to HIV-1 envelope vari-
able regions 1 and 2 (V1 and V2) (61, 62). We have also recently
demonstrated that MAbs CH58, CH59, HG107, and HG120 iso-
lated from RV144 vaccinees share the same V2 epitope region with
the broad neutralizing antibody PG9, have neutralizing activity
against tier 1 isolates, and mediate the killing of field isolate HIV-
1-infected CD4 T cells (63). PG9 bNAb binds both to amino
acids K168 and K169 (positions 164 and 172 in HXB2 numbering)
of the V2 region and binds to glycans at N156 and N160 in that
FIG 7 Levels and specificities of serum antibodies of immunized guinea pigs to HIV-1 Envs. Serum samples of immunized guinea pigs grouped by immunogens
of consensus (red), chronic (blue), and T/F (green) were tested in ELISA for binding to the autologous Env in serial 1:3 dilutions (1:30 to 1:5,314,410) to compare
the levels of antibody responses for the different classes of immunogens. Prebleed serum was used as a negative control and had negligible binding to HIV-1 Env.
Serum binding antibody titers were expressed as the EC50 (reciprocal serum dilutions) on the y axis (A). The open circles in each column represent the EC50 for
each member of a group of animals immunized with the same immunogen; the filled circles represent the geometric mean of the group. This geometric mean
score was used to represent each of the immunogens and to statistically compare the classes of vaccines. The median value of the geometric means is indicated by
the horizontal bar. Vaccine classes (consensus, chronic, and T/F) were compared by using a Kruskal-Wallis omnibus test; if it was significant (P  0.003), pairwise
comparisons were then made between the vaccine classes, and consensus and chronic vaccines were shown to show higher-magnitude autologous responses than
T/F vaccines. The immune sera were also tested for blocking the binding of sCD4 to HIV-1 Env JRFL gp140 (B), MAbs 1b12 to HIV-1 Env JRFL (C), PG9 to HIV-1
Env A244 (D), and 2G12 to HIV-1 Env JRFL (E) at a 1:50 serum dilution. The percentage of inhibition of the binding by guinea pig sera of each group was plotted
and statistically compared in a in a manner analogous to the strategy described in panel A, except that for panels B to E, the filled circles represent the mean value
for each vaccine group and not the geometric mean. Among the inhibition assays (B-E), only the inhibition of PG9 binding was statistically significant (D), and
the T/F vaccines had lower levels of PG9 inhibition than either consensus or chronic.
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same region (64). The inhibitory binding of PG9 binding to Env
by our guinea pig sera most likely reflects the induction of V2
antibodies targeted at or near this region. This region contributes
to an epitope recognized by V2 anti-peptide antibodies that are
frequently induced with Env immunization as well as by PG9
bNAb, but the PG9 inhibition we observed in this study does not
necessarily reflect the induction of anti-glycan PG9-like bNAbs.
It is well known that the antigenicity of an Env does not predict
its capacity to induce an immune response to an expressed
epitope. Nonetheless, we reasoned it is important for candidate
Env immunogens to be as antigenic as possible in terms of bNAb
binding. Thus, of the 18 T/F, chronic, and consensus Envs, we
found that B.63521 and B.6240 Env gp140s expressed all of the
Env epitopes studied. In addition, despite being artificial con-
structs, several of the consensus Envs also expressed each of these
epitopes, in particular B.con_03 and G.con. CON-S had particu-
larly high levels of reactivity to most of the panel of MAbs, com-
parable to the best T/F strains (Tables 1 and 2). These epitopes
included the epitopes recognized by the bNAbs 2F5 (65), 4E10
(66), PG9, PG16, and VRC01 (57) and the glycan bNAb, 2G12
(67), in addition to the PG9 and PG16 (17) V2V3 conformational
epitope bNAbs (64), as well as CH01-CH04 MAbs against the
same V1/V2 bNAb epitope (68, 69). Thus, choosing candidate
recombinant Env immunogens that react with V1/V2 conforma-
tional epitope bNAbs, as well as other bNAbs, seems prudent. In
this regard, the C.1086 gp120 and a chronic C.TV-1 gp120 Env
pair have been selected for production as a bivalent clade C gp120
boost for a poxvirus prime-gp120 protein boost clinical trial. The
antigenicity of these two gp120 Envs are complementary with
C.1086, binding better to sCD4, 17b (CCR5 bs), A32 (C1, ADCC),
VRC01 (CD4bs), 19b (V3), and various V2 MAbs (e.g., 2158),
whereas C.TV-1 gp120 binds better to other V2 antibodies (830A,
697-D), and in particular to PG9 and PG16 V1V2 bNAbs (S. A.
Alam, H.-X. Liao, S. Barnett, and B. F. Haynes, unpublished data).
CON-S Env will be tested in a phase I human trial, and its immu-
nogenicity in terms of NAb responses in humans will be explored.
In a recent immunogenicity test in macaques of the vaccine con-
structs going into phase I human trials, CON-S was shown to be
highly immunogenic and to elicit potent tier 1 and some moderate
tier 2 NAb responses, in good accord with the results of the com-
parative vaccination study in guinea pigs presented here (B. F.
Haynes, H.-X. Liao, B. Korber, S. Santra, and N. Letvin, unpub-
lished data).
The findings we present here are based on using gp140 Envs
that may have incremental immunological advantages over gp120
(2, 34, 70), although gp120 is easier to produce and so historically
has been used in human trials (62, 71, 72). In several studies, stable
soluble trimeric HIV-1 Envs have elicited more potent neutraliz-
ing antibodies compared to gp120s, but still of limited breadth
(70, 73). Stable, rigorously homogeneous trimers that have anti-
genic properties markedly different from those of monomeric
gp120 induced more potent neutralizing antibodies than those
elicited by the corresponding gp120 monomers; however, anti-
bodies induced by such stable trimers also have very limited neu-
tralizing potency and breadth (73, 74). It remains to be definitively
determined whether gp140 Env constructs are indeed superior
and worth the production cost for use in clinical trials.
The key criterion for Env immunogen selection should be Env
immunogenicity. We found three distinct patterns of Env immu-
nogenicity in isolates from acute infection, chronic infection, and
in silico-designed consensus Envs. Although these patterns were
statistically significant, our sample size for each group was limited,
and the clade compositions of the groups were biased because of
reagent availability when the study was initiated. Further studies
to confirm these findings are warranted. Chronic Envs gave the
poorest tier 1 and only weak sporadic tier 2 neutralization re-
sponses. Consensus Envs had a pattern of high NAb titers against
tier 1 Envs, and moderately high titer responses (higher than T/F
immunogens) to a subset of tier 2 Envs. The group M CON-S Env
is the optimal Env tested among the consensus group and yielded
the highest responses overall. In contrast, the T/F Envs induced
tier 1 responses of lower magnitude, but which consistently had
greater neutralization breadth, inducing low titer neutralizing re-
sponses to most tier 2 HIV-1 strains. The levels of antibody needed
for protection in the SHIV/macaque model were initially thought
to be quite high and difficult to achieve in vivo (100-fold over the
in vitro 50% infectious concentration [IC50] levels) (75–78). How-
ever, recently lower levels of neutralizing antibodies were shown
to be needed for protection against mucosal challenge in this
model (79), and very low levels of neutralizing antibodies have
been shown in humans in vivo to induce autologous T/F virus
escape mutants (22), providing hope that low levels of NAbs may
be able to prevent HIV-1 acquisition at mucosal sites. The distinc-
tive patterns suggest different epitopes may be targeted in re-
sponses to consensus and T/F immunogens, and both classes of
response may be beneficial in different ways in a vaccine setting. If
the NAb effects were additive, as some studies suggest (69, 80), and
both types of response can be triggered simultaneously, a polyva-
lent combination of complementary immunogens may prove a
useful vaccine strategy. Analysis of these and similar data sets
should be useful both for the choice of individual candidate Env
immunogens and for identifying the most promising polyvalent
Env mixtures for immunogenicity testing in nonhuman primates
and humans.
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